Neos Therapeutics (NEOS) Downgraded to Hold at Zacks Investment Research

Neos Therapeutics (NASDAQ:NEOS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports.

According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “

Separately, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 price target on shares of Neos Therapeutics in a research note on Wednesday, March 27th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Neos Therapeutics presently has an average rating of “Buy” and an average target price of $9.69.

Shares of NEOS stock opened at $2.29 on Thursday. Neos Therapeutics has a 52 week low of $1.40 and a 52 week high of $8.70. The company has a debt-to-equity ratio of 5.51, a current ratio of 1.55 and a quick ratio of 1.37.

Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. The business had revenue of $15.39 million during the quarter, compared to analysts’ expectations of $18.90 million. On average, analysts predict that Neos Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its holdings in Neos Therapeutics by 162.5% in the third quarter. JPMorgan Chase & Co. now owns 267,417 shares of the company’s stock worth $1,297,000 after purchasing an additional 165,555 shares in the last quarter. Diag Capital Management LP bought a new position in Neos Therapeutics in the fourth quarter worth $278,000. Franklin Resources Inc. raised its holdings in Neos Therapeutics by 8.4% in the third quarter. Franklin Resources Inc. now owns 2,493,239 shares of the company’s stock worth $12,092,000 after purchasing an additional 193,500 shares in the last quarter. Stonepine Capital Management LLC raised its holdings in Neos Therapeutics by 1,747.2% in the fourth quarter. Stonepine Capital Management LLC now owns 4,210,153 shares of the company’s stock worth $6,947,000 after purchasing an additional 3,982,234 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its holdings in Neos Therapeutics by 164.7% in the fourth quarter. Sphera Funds Management LTD. now owns 2,201,697 shares of the company’s stock worth $3,633,000 after purchasing an additional 1,370,000 shares in the last quarter. Institutional investors and hedge funds own 50.83% of the company’s stock.

About Neos Therapeutics

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Read More: How is diluted EPS different from basic EPS?

Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.